Abstract Dopamine b-hydroxylase (DBH) and norepinephrine (NE) transporter (NET) are the noradrenergic phenotypes for their functional importance to noradrenergic neurons. It is known that in vivo N-(2-chloroethyl)-Nethyl-2-bromobenzylamine (DSP4) treatment induces degeneration of noradrenergic terminals by interacting with NET and depleting intracellular NE. However, DSP4's precise mechanism of action remains unclear. In this study various biochemical approaches were employed to test the hypothesis that DSP4 down-regulates the expression of DBH and NET, and to determine molecular mechanisms that may be involved. The results showed that treatment of SH-SY5Y neuroblastoma cells with DSP4 significantly decreased mRNA and protein levels of DBH and NET. DSP4-induced reduction of DBH mRNA and proteins, as well as NET proteins showed a time-and concentrationdependent manner. Flow cytometric analysis demonstrated that DSP4-treated cells were arrested predominantly in the S-phase, which was reversible. The arrest was confirmed by several DNA damage response markers (phosphorylation of H2AX and p53), suggesting that DSP4 causes replication stress which triggers cell cycle arrest via the S-phase checkpoints. Moreover, the comet assay verified that DSP4 induced single-strand DNA breaks. In summary, the present study demonstrated that DSP4 down-regulates the noradrenergic phenotypes, which may be mediated by its actions on DNA replication, leading to replication stress and cell cycle arrest. These action mechanisms of DSP4 may account for its degenerative consequence after systematic administration for animal models.
Introduction
The dopamine b-hydroxylase (DBH, EC 1.14.17.1) and norepinephrine (NE) transporter (NET) are the important proteins of the noradrenergic neurons for their specific functional characteristics in these neurons (Kaufman and Friedman 1965; Chan-Palay and Asan 1989; Barker and Blakely 1995) . DBH catalyzes the oxidation of dopamine to NE and is expressed exclusively in the noradrenergic and adrenergic neurons in the brain. DBH is not the ratelimiting enzyme for NE synthesis. However, it was reported that the amount of DBH available is also a key factor in determining the rate of NE synthesis (Kobayashi et al. 1994; Kim et al. 2002) . The NET is located on presynaptic terminals of noradrenergic neurons in the central and peripheral nervous system (Iversen 1971) , and functions to reuptake more than 90 % of released NE into the presynaptic terminals (Axelrod and Kopin 1969) . As this reuptake is the main mechanism for inactivation of NEstimulated transmission, alterations of NET expression remarkably would affect NE levels in the synapses and, in turn, highly influence noradrenergic transmission. As such, changes in the expression of these proteins not only affect NE levels in vitro and in vivo, but also reflect alteration in activity and function of these neurons in the brain. Therefore, measurement of their expression can yield important information regarding the functional status of neuronal cells and underlying mechanisms of neurotransmission (Zigmond et al. 1989) .
The effects of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on NE levels in the peripheral and central noradrenergic system were first reported several decades ago (Ross 1976 ). DSP4 can cross the blood-brain barrier and accumulate intraneuronally. In vivo DSP4 selectively damages noradrenergic projections originating from the locus coeruleus (LC) by interacting with the NE reuptake system and depleting intracellular NE, finally inducing degeneration of noradrenergic terminals (Winkler 1976; Ransom et al. 1985; Dooley et al. 1987; Howard et al. 1990; Prieto and Giralt 2001) . Thus, DSP4 has been widely used as a noradrenergic neurotoxin. However, the precise mechanism of action of DSP4 remains unclear. In addition, little data have been reported from in vitro studies on the mechanism of DSP4-induced neuronal degeneration. Thus, elucidating the molecular mechanism by which DSP4 evokes its neurodegenerative effect may promote the effort to find novel therapeutic strategies for treatment of degenerative diseases.
Aberrant cell cycle activity and DNA damage have been observed during the progression of neurodegenerative conditions. Many cytotoxic and genotoxic agents including neurotoxins arrest the cell cycle at the different phases (Sontag et al. 2008) . Also, neurons are continuously exposed to endogenous and environmental DNA-damaging insults, inducing DNA strand breaks and base adducts, eventually leading to neurodegeneration. Whether these events are involved in DSP4's toxicity to the noradrenergic neurons is an important but unresolved issue. Genotoxic damage can occur in any of the four phases of the cell cycle, G1, S, G 2 , or M. Neurons are terminally differentiated cells and no longer progress through the cell cycle. However, neurons require continuous gene expression to maintain their high metabolism and machinery for neurotransmission and genome integrity is essential for such an expression program. Thus, like cycling cells the LC and other neurons remain susceptible to DNA damage and would be expected to have active DNA damage response (DDR) mechanisms and cell cycle checkpoints to remedy such damage. Ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) protein kinases are early damage-sensing components of DDR pathways, especially in response to double-and single-strand DNA breaks (Abraham 2001) . Protein substrates of the activated ATM and ATR kinases include histone H2AX which is phosphorylated at serine 139 (cH2AX) (Burma et al. 2001; Ward and Chen 2001) and the tumor suppressor protein p53 which is phosphorylated at serine 15 (phosphop53 ser15 ) (Hammond et al. 2002) . cH2AX tags the chromatin sites of DNA damage to initiate the recruitment of DNA repair factors (Zarei and Stephenson 2002; Sontag et al. 2008) while the phospho-p53 ser15 enhances transcription of DDR genes and modifies the interaction of DNA metabolism proteins (Serrano et al. 2012) . In cycling cells responses to DNA damage arrest cell cycle progression to allow DNA repair; however, the sequence of events for the DDR in highly differentiated, non-dividing cells have not been addressed in part because of the experimental limitations in performing such studies.
In this study, we used SH-SY5Y, an immortal neuroblastoma cell line which expresses the noradrenergic markers DBH and NET, to test the hypothesis that DSP4 down-regulates their expression. Further efforts have been focused on the exploration of possible mechanisms underlying DSP4-induced down-regulation of these noradrenergic phenotypes and for DSP4 toxicity associated with DDR marker proteins.
Materials and Methods

Cell Culture and Drug Exposure
The human neuroblastoma cell line SH-SY5Y was used in these experiments (Biedler et al. 1978) . SH-SY5Y cells were maintained in a 1:1 mix of RPMI 1640 and F12 media, which was supplemented with 10 % heat-inactivated fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 lg/ml) at 37°C in humidified air containing 5 % CO 2 . Culture medium and supplements were obtained from Gibco-Invitrogen (Carlsbad, CA, USA). Cells were seeded into 6-well or 100-mm plates. Drug exposures were started after 24 h of each subculture. DSP4 (Sigma, St Louis, MO, USA) dissolved in distilled water at 50 mM was diluted with culture media and added to cells to a final concentration of 5, 10, or 50 lM, alone or in combination with the ATM inhibitor KU55933 (10 lM, Selleckchem, USA), and/or the ATR inhibitor Nu6027 (10 lM, Santa Cruz, CA, USA) for the times as indicated in the text. The selection of the concentration of DSP4 was based on the reports about its IC50 in the literature (Boksa et al. 1989; Tieu et al. 1999; Wenge and Bonisch 2009 ) and our preliminary experiments. Only SH-SY5Y cells prior to passage 15 were used. Cell viability was determined by exclusion of Trypan Blue dye; cell viability was 90-95 % in the untreated cells.
RNA Isolation, RT-PCR, and Relative Quantitative qPCR Analysis SH-SY5Y cells with or without DSP4 treatment were collected from 6-well plates and isolation of total RNA was carried out using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. Quality and quantity of total RNAs were detected at 260 and 280 nm using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies LLC, Wilmington, Delaware, CA, USA). Equal amounts of total RNA (1 lg) from each sample were primed with random primers and reverse transcribed to cDNAs using the Superscript First-strand Synthesis Kit (Invitrogen, Grand Island, NY, USA) following the manufacturer's recommendation. Aliquots of first strand cDNA (1 ll for DBH, NET, or GAPDH) were amplified by PCR in a 25 ll reaction mix containing Platinum PCR Supermix (Invitrogen, Grand Island, NY, USA) and primers at appropriate concentrations in an Eppendorf Thermal Cycler (Eppendorf, Hamburg, Germany 0 . All reactions were performed according to the following protocol: 2 min at 50°C, 2 min at 95°C, followed by 45 cycles of 18 s at 95°C and 45 s at annealing temperature (NET 60°C, DBH 56°C, GAPDH 56°C), then continued with the melting curve analysis (55-90°C) to verify the product specificity. Annealing temperature of each gene was determined by running gradient qPCR with a range of annealing temperatures starting from 55 to 66°C. Comparative cross threshold (C t ) method was used to measure gene expression in response to DSP4 treatments.
Western Blotting Analysis
Whole cell extracts for western blot analysis were prepared by lysing cells in ice-cold Nonidet P-40 (NP-40; Sigma, St Louis, MO, USA) buffer (0.5 % NP-40, 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA) for 30 min, after which nuclei and cell debris were removed by centrifugation at 12,000 rpm for 10 min at 4°C. An equal volume of 29 sodium dodecyl sulfate (SDS) gel-loading buffer then was added to the supernatant and the samples were denatured at 70°C for 5 min. Protein concentrations in cell extracts were quantified prior to addition of the loading buffer with the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA, USA). Proteins (40 lg) were electrophoretically separated on a 10 % or a 15 % SDS-polyacrylamide gel and electro-blotted onto a nitrocellulose membrane (Amersham Life Sciences, Buckinghamshire, UK). For protein detection, the blots were, respectively, probed with a mouse monoclonal anti-NET antibody (1:1,000 dilution; Mab Technology Inc., Stone Mountain, GA, USA, or 1:1,000; Alpha Diagnostic Intl. Inc., San Antonio, Texas USA), anti-DBH antibody (1:500 dilution; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-replication protein A (RPA) antibody (1:1,000 dilution, R3280, Sigma-Aldrich, St Louis, Mo, USA), anti-cH2AX antibody (1:1,000 dilution, Bethyl Laboratories, Inc., Montgomery, TX USA), or an anti-phospho-p53 ser15 antibody (1:1,000 dilution, Cell Signaling Technology, Inc., Danvers, MA, USA). A horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibody (1:5,000 dilution; Amersham Life Sciences, Buckinghamshire, UK) was used as the secondary antibody. The membranes were then subjected to enhanced chemiluminescence (Amersham Life Sciences, Buckinghamshire, UK) or super enhanced ECL (Sigma Chemical Co., St Louis, MO, USA) and autoradiography. To check for equal loading and transfer, the membranes were reprobed with a mouse IgG monoclonal anti-b-actin antibody (1:5,000 dilution, Amersham Life Sciences, Buckinghamshire, UK).
Flow Cytometry
Cells, sub-cultured in a 6-well plate at 2 9 10 4 cells/well, were exposed to DSP4 (5 and 50 lM) for 24 h. After washing with 37°C phosphate buffered saline (PBS), 200 ll of 0.25 % trypsin-EDTA (Gibco, Carlsbad, CA, USA) was added per well and the plate was incubated at 37°C for 1 min. The trypsin was aspirated off and the cells were suspended with 1 ml ice-cold PBS containing 0.5 mM EDTA (PBSE). The cells were collected by centrifugation at 3,000 rpm for 10 min at 4°C and fixed by slowly adding 1 ml ice-cold 70 % ethanol to resuspend the cells. The cells were stored at -20°C for 12-24 h, then collected at 3,000 rpm for 10 min at 4°C. The cells were washed once with ice-cold PBSE, then recentrifuged and resuspended in 300 ll of freshly prepared PBSE containing 20 lg/ml propidium iodide (Sigma, St Louis, MO, USA) and 20 lg/ml DNase-free RNase A (Invitrogen, Grand Island, NY, USA). After incubation at 37°C for 30 min, the cells were analyzed on an Accuri C6 flow cytometer. The population of G0/G1, S, and G2/M was determined using C6 Flow Cytometer Software. The results are expressed as percentage of the attached cells in each phase.
Immunofluorescence 2 9 10 4 cells were grown on coverslips in 24-well plates and treated with or without DSP4 (5, 10, or 50 lM) for 24 h. The cells were fixed with 4 % paraformaldehyde for 15 min and permeabilized with 0.2 % Triton X-100 in PBS for 10 min. Coverslips were then blocked with 5 % goat serum in PBS for 1 h, and incubated overnight with primary antibodies (anti-cH2AX: 1:200 dilution, GeneTex Inc., Irvine, CA, USA), and an anti-phospho-p53 ser15
(1:400 dilution, Cell Signaling Technology, Inc., Danvers, MA, USA). After three 10-min washes with PBS, the coverslips were incubated with the secondary antibodies [Alexa Fluor Ò 488 Goat Anti-Rabbit IgG (H?L); Alexa Fluor Ò 568 Goat Anti-Mouse IgG (H?L), EMD Millipore Corporation, Billerica, MA, USA] diluted in PBS with 5 % goat serum. Coverslips were mounted onto microscope slides using Fluoromount-G mounting medium (Invitrogen, Grand Island, NY, USA). Slides were viewed and photographed at 1009 magnification using an EVOS inverted fluorescent microscope (Advanced Microscopy Group) with attached CCD camera.
Comet Assay
SH-SY5Y cells were treated with different concentrations of DSP4 (5, 10, or 50 lM) or camptothecin (CPT, 10 lM) for 24 h. Then, neutral and alkaline comet assays were carried out using the Comet Assay System (Trevigen Inc., Gaithersburg, MD, USA) according to the manufacturer's instructions. Fluorescence images were captured at 109 magnification. At least 50 cells were assessed per treatment. In parallel with the comet assay, cell cultures with the same treatments were harvested for the protein analysis by western blotting.
Statistics
All experimental data are presented in the text and graph as the mean ± SEM. The number of replicates is enumerated in the figure legends. Data were analyzed using one-way analysis of variance (ANOVA), which was followed by a post hoc Newman-Keuls test for planned comparisons.
Results
DSP4 Treatment Down-Regulates the Expression of DBH and NET in a Time-and ConcentrationDependent Manner
Effects of DSP4 treatment on mRNA and protein levels of noradrenergic phenotypes in human SH-SY5Y cells were examined. As shown in Fig. 1 , exposure of cells to 50 lM DSP4 (this concentration was selected based on preliminary experiments and the literature) for different times resulted in a significant reduction of DBH (F 4,45 = 34, p \ 0.0001) and NET (F 4,34 = 30.8, p \ 0.0001) proteins. Post hoc tests revealed that compared to the control (0 time), DSP4-induced reduction of DBH/NET protein levels was timedependent. For the concentration course, cells were exposed to DSP4 at concentrations of 5, 10, and 50 lM for 24 h. qPCR analyses showed that DSP4 significantly decreased mRNA levels of DBH (F 3,48 = 85.2, p \ 0.0001) and NET (F 3,44 = 17.97, p \ 0.001) (Figs. 2a, 3a) . Consistently, protein levels of DBH (F 3,27 = 56.2, p \ 0.0001) and NET (F 3,36 = 69.3, p \ 0.0001) also were significantly reduced as analyzed by western blotting (Figs. 2b, c, 3b, c) . Post hoc tests demonstrated that DSP4-induced reduction in mRNA and protein levels of DBH, as well as NET proteins showed in a concentration-dependent manner.
It was reported that the effects of DSP4 on NE levels in vivo are reversible (Jaim-Etcheverry and Zieher 1980; Hallman et al. 1984b; Wolfman et al. 1994; Srinivasan and Schmidt 2004; Szot et al. 2010) . The recovery of DBH/ NET protein levels from inhibition by DSP4 was tested further. Cells were exposed to 50 lM for 24 h and after brief washing with PBS, cells were then maintained in fresh medium in the absence of DSP4 for 24, 48, 72, and 96 h. Western blotting analysis showed that washing-out of DSP4 marked affected DBH/NET protein levels (F 5,42 = 7.56, p \ 0.01 for DBH; F 5,42 = 30.48, p \ 0.0001). While DBH levels were fully recovered within 24 h, it took 48 h for full recovery of NET protein levels (p \ 0.01). Nevertheless, these results indicated that DSP4-induced inhibition of DBH and NET expression in SH-SY5Y cells is reversible (Fig. 4) .
DSP4 Treatment Leads to Cell Cycle Arrest
To further study the action mechanisms of DSP4, SH-SY5Y cells were exposed to 5 or 50 lM DSP4 for 24 h and the effects of these single-dose treatments on cell growth and viability were studied by trypan blue staining. At 5 lM, DSP4 inhibited cell proliferation by 25 % (p \ 0.05), whereas 50 lM DSP4 inhibited proliferation by 50 % (p \ 0.001), compared to the control group after 24 h (Fig. 5a ). This result suggests that the cell cycle was arrested. S-phase checkpoint monitors the integrity of the genome and halts DNA synthesis, arresting cells in S-phase, following DNA damage (Bartek and Lukas 2001) . Flow cytometry was then used to determine whether cell (2014) 25:193-207 197 cycle transit was altered by DSP4. The DNA profile clearly demonstrates that DSP4 profoundly affects the SH-SY5Y cell cycle. In an untreated cell population 52.63, 18.73, and 27.17 % of the cells were distributed among the G1-, S-, and G2/M-phases, respectively (Fig. 5b, c) . After a 24-h treatment with 5 or 50 lM DSP4 the percentage of SH-SY5Y cells in S-phase increased to 28.77 and 32.83 %, respectively, compared to 18.73 % in untreated control cells. These cytometric results demonstrate that DSP4-treated SH-SY5Y cells accumulated predominantly in S-phase due to cell cycle arrest. Next, we examined whether S-phase-arrested cells could resume cell cycle transit after removal of DSP4. Cells were treated with 50 lM DSP4 for 24 h, then rinsed with PBS and maintained in fresh medium without DSP4 for another 12 or 24 h before analysis by flow cytometry. As shown in Fig. 6 , arrested cells resumed cycle transit within 12 or 24 h after DSP4 removal. Although more cells were in S-phase compared with the control, the proportion of cells in G1-phase returned to normal. Interestingly, after removal of DSP4 for 24 h, fewer cells were in G2-phase compared to the control group (p [ 0.05). These data indicate that DSP4-arrested cells were able to resume cell cycle transit after removal of DSP4.
DSP4 Treatment Induces DDRs
How does DSP4 treatment lead to cell cycle arrest with an accumulation of cells in S-phase? To address this question, SH-SY5Y cells were treated with 50 lM DSP4 for different times. As a positive control, one group of cells was treated for 2 h before cell harvest with CPT alone, a cytotoxic drug which inhibits topoisomerase I, thus inducing DNA double-strand breaks (DSBs) in the subsequent S-phase (Del Bino et al. 1992; Kurose et al. 2006 ). The harvested cell samples were analyzed by western blotting for the DDR markers cH2AX, phosphor-p53 ser15 , and hyperphosphorylation of RPA. As shown by Fig. 7 , cH2AX and phosphor-p53 ser15 levels were significantly increased at 2 or 4 h, respectively, after DSP4 exposure (F 6,42 = 46.6, p \ 0.001 for cH2AX; F 6,42 = 85.5, p \ 0.001 for p-p53 ser15 ), indicating DNA damage appeared earlier than reduction of DBH/NET expression.
In the separate experiment, cells were exposed to DSP4 (5, 10, or 50 lM) for 24 h. Increased cH2AX levels were proportional to DSP4 concentrations (Fig. 8a, b) , suggesting that DNA strand breaks were induced by DSP4. Also, nuclear cH2AX foci were observed by immunofluorescence with the number of foci increasing proportionally with DSP4 concentrations or exposure time (Fig. 9a) . Tumor suppressor protein p53 also is phosphorylated at serine 15 in response to DNA damage or replication stress (Prieto and Giralt 2001) . The level of phospho-p53 ser15 also is increased in response to DSP4 treatment; this increase in phospho-p53 ser15 is proportional to DSP4 concentration as determined by western blots (Fig. 8c, d ) and by immunofluorescence (Fig. 9b) .
Human RPA is a single-strand DNA-binding protein that is involved in many aspects of DNA metabolism (Zou et al. 2006) . The 32 kDa subunit of RPA (RPA32) is hyperphosphorylated in response to DNA DSBs and to some other types of DNA damage (Zou et al. 2006) . Also, CPT induces DNA DSBs and RPA hyperphosphorylation (Murren et al. 1996; Liu et al. 2000) , which appears as a slower migrating band on SDS-polyacrylamide gels. To determine if RPA becomes hyperphosphorylated in response to DSP4 treatment SH-SY5Y cells were treated Fig. 4 Recovery of DBH/NET protein levels from inhibition by DSP4. SH-SY5Y cells were exposed to 50 lM DSP4 for 24 h (DSP4) and then incubated in fresh media in the absence of DSP4 for 24 (R24 h), 48 (R48 h), 72 (R72 h), and 96 h (R96 h) after brief washing by PBS. The control cells were exposed to the vehicle (con). a Autoradiograph obtained by western blotting. b, c The quantitative analysis of band densities in western blotting of DBH/NET. Values of protein levels of DBH/NET were normalized to those of b-actin in the same measurement. The graphic data represent averages obtained from seven separate experiments. ***p \ 0.001, compared to the control group (con); ### p \ 0.001, compared to the DSP4 group; &&& p \ 0.001, compared to the R24 h group with DSP4 (5, 10, or 50 lM) for 24 h. As a positive control other cells were treated with CPT for 2 h before cell harvest. Interestingly, the hyperphosphorylated-RPA32 (hyp-RPA32) band was detected only in the CPT-treated cells (Fig. 8e) .
DSP4 Induces Activation of Both ATM and ATR Pathways
Cell cycle checkpoints are regulatory pathways that govern the order and timing of cell cycle transitions to insure completion of one cellular event prior to commencement of the next cell cycle phase Hatip-Al-Khatib and Bolukbasi 1999). The key regulators of the checkpoint pathways in the mammalian DDR are the ATM and ATR protein kinases, members of the serine-threonine PIKK kinases family (Abraham 2001; Shiloh 2001) . Although ATM and ATR appear to phosphorylate many of the same cellular substrates (Kim et al. 1999) , they generally respond to distinct types of DNA damage. ATM and ATR inhibitors were used to elucidate the role of these kinases in the DSP4-induced DDR. SH-SY5Y cells were treated with ATM or ATR inhibitors, alone or in combination, for 1 h before continuous exposure to 50 lM DSP4 for 24 h. Western blotting revealed that ATM inhibition significantly decreased the level of DSP4-induced cH2AX, compared to that of cells treated with DSP4 alone. In contrast, ATR inhibition increased the level of DSP4-induced cH2AX over that of cells treated with DSP4 alone. Treatment with both ATM and ATR inhibitors resulted in no net change of cH2AX levels, compared to that of the group treated with DSP4 alone (Fig. 10a, b) . These results indicate that ATM is involved in cH2AX formation after DSP4 treatment. This is consistent with the significant reduction in DSP4-dependent phosphorylation of p53 ser15 by ATM inhibition and increased levels by ATR inhibition. Similarly, treatment with both kinase inhibitors did not show a net reduction in phospho-p53 ser15 levels below compared to DSP4 treatment alone (Fig. 10c, d ). These results indicate that cH2AX and phospho-p53 ser15 formation are downstream product primarily of ATM after DSP4 treatment. Neurotox Res (2014) 25:193-207 199 DSP4 Induces Single-Strand DNA Breaks (SSBs)
To further explore the type of DNA damage induced by DSP4 treatment, SH-SY5Y cells treated with DSP4 (5, 10, or 50 lM) for 24 h were analyzed by neutral or the alkaline comet assays. These assays detect DNA double-versus singlestrand breaks, respectively, by measuring the formation of the nuclear DNA tail (comet) after single-cell gel electrophoresis. As shown in Fig. 11 , no obvious nuclear tails were observed in the neutral comet assay after DSP4 treatment, indicating that DSP4 did not lead to detectable DNA DSBs. However, exposure of SH-SY5Y cells to DSP4 resulted in extensive SSBs as reflected in the significant tail lengths observed in the alkaline comet assay (Fig. 11, bottom) .
Discussion
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine is a wellknown neurotoxin that selectively damages the noradrenergic projection originating from the LC (Jonsson et al. 1981; Fritschy et al. 1990 ). In the present study, SH-SY5Y neuroblastoma cell line, which naturally expressing DBH and NET (Richards and Sadee 1986 ) but neither the serotonin nor dopamine transporters (Lode et al. 1995) , was used to examine the potential molecular mechanisms underlying DSP4 action on noradrenergic phenotypes. The main findings are: (1) DBH and NET expression in SH-SY5Y cell line was down-regulated by DSP4 and DSP4-induced reduction of their protein levels and DBH mRNA level exhibited a concentration and time-dependent manner. (2) DSP4 treatment resulted in cell cycle arrest predominantly in S-phase. (3) Removal of DSP4 allowed the arrested cells to resume the cell cycle and to replenish the reduced DBH and NET protein. (4) DSP4-induced cell cycle arrest was possibly caused by DNA damage as DSP4 treatment significantly increased the DDR markers cH2AX and phospho-p53 ser15 . (5) DSP4 treatment activated the ATM pathway as part of the DDR. (6) DSP4 treatment of SH-SY5Y cells induced DNA SSBs but not DSBs. Thus, these results suggest that down-regulation of the noradrenergic phenotypes caused by DSP4 may stem from the DSP4-induced DNA damage, which activated the ATM pathway and eventually resulted in cell cycle disruption. Previously, most studies of DSP4 neurotoxicity were carried out under in vivo conditions. DSP4 has been considered to interact at high affinity with the NE reuptake sites on the noradrenergic terminals which were degenerated due to the alkylation of diverse vital neuronal structures (Lee et al. 1982; Hallman and Jonsson 1984a; Dudley et al. 1990 ). Also, DSP4-induced reduction of [ 3 H]desipramine binding (Lee et al. 1982 ) suggested a damaged NE reuptake. Furthermore, a reduced immunoreactivity of DBH and tyrosine hydroxylase in the LC and other brain regions caused by administration of DSP4 revealed an inhibition of noradrenergic phenotypes (Ross 1976; Gordon et al. 1999; Prieto and Giralt 2001; Kalinin et al. 2006; Waterman and Harding 2008; Engler et al. 2010) . In the present study DSP4 treatment was found to drastically down-regulate expression of the DBH and NET in 0 ,4-diamidino-2-phenylindole, a fluorescent dye that strongly binds to DNA as a nuclear counterstain SH-SY5Y cells, which is consistent with those observations in vivo. These results confirm that the neurotoxicity of DSP4 is primarily mediated through inhibition or reduced expression of the noradrenergic phenotypes: reduced expression of DBH/NET diminishes the synthesis/ reuptake of NE, and finally leads to lower levels of NE in the brain.
Reduced expression of DBH/NET could be the end result rather than the cause of the neurodegeneration. DNA is vulnerable to damage throughout the cell cycle due to diverse types of pathological insults including oxidative stress and cytotoxins which upset DNA metabolism. Though neurons are non-cycling cells neurotoxicity may be mediated by similar metabolic upsets. One consequence is DNA damage induced by active metabolites which cause DNA base adducts or strand breaks (Katyal and McKinnon 2008) . In response to DNA damage, checkpoint surveillance mechanisms initiate signaling cascades which coordinate cell cycle arrest and facilitate DNA repair (Shiloh 2003; Bakkenist and Kastan 2004; McGowan and Russell 2004) . If these checkpoint surveillance mechanisms fail in neurons, neurodegeneration eventually occurs (Lavin 1999; Cho and Liang 2011) . There has been a slow but steady accumulation of evidence of DNA damage in various neurodegenerative diseases (Robison and Bradley 1984) . For example, an increase of DNA strand breaks in neurons Fig. 10 Res (2014) 25:193-207 203 has been reported in Alzheimer disease (AD) (Adamec et al. 1999) and Huntington disease (Anne et al. 2007 ).
Damage to mitochondrial DNA also has been found in Parkinson's disease (PD) (Zhang et al. 1999) . Therefore, DNA damage with alteration of cell cycle is likely involved in DSP4-induced degeneration of noradrenergic neurons. The present study demonstrated that exposure of cells to 50 lM DSP4 for 24 h induced about 50 % cell proliferation inhibition. The flow cytometric analysis showed that DSP4 treatment for only 24 h induced cell cycle arrest in S-phase. DDR measurements confirmed a significant increase in cH2AX and phospho-p53 ser15 , as well as increased frequencies of nuclear cH2AX foci; such foci normally represent formation of protein complexes at sites of DNA damage (Sontag et al. 2008 ). All these observations indicated that DSP4-induced cell cycle arrest occurred primarily in S-phase and was mediated through DNA damage signaling.
DNA damage and replication stress responses are a cascade signal transduction process. The DDR consists of multiple interconnected pathways which impact the cell cycle, DNA replication and repair, transcriptional regulation, chromatin remodeling, and other cellular metabolic processes (Zhou and Elledge 2000; Rouse and Jackson 2002) . Actually, the activation of DNA damage-induced signaling pathways serves to arrest the cell cycle while DNA repair occurs. In response to DNA strand breaks and during replication stress, ATM and ATR kinases are considered as a major physiological mediators for the phosphorylation of H2AX and p53 (Rogakou et al. 1998; Kastan and Lim 2000; Bakkenist and Kastan 2003) . cH2AX and phospho-p53 ser15 function as downstream mediators in this signaling pathway. The present study demonstrated that these signal pathways are involved in the DSP4-induced down-regulation of the noradrenergic phenotypes. After exposure of cells to DSP4, increased levels of cH2AX foci and nuclear phospho-p53 ser15 were proportional to DSP4 concentrations (Fig. 9) . Furthermore, the ATM inhibitor significantly blocked the DSP4-induced enhancement of cH2AX and phospho-p53 ser15 levels (Fig. 10) . Thus, ATM signaling pathways play a significant role in the DDR to DSP4's toxic effects.
DNA strand breaks can occur as either SSBs or DSBs. Compared to DSBs, SSBs are the more common lesion induced by exogenous genotoxins such as ionizing radiation and alkylating agents (Jeppesen et al. 2011) . Also, SSBs can collapse a replication fork and be converted into DSBs, a threat to genetic stability if not dealt with properly (Caldecott 2004) . DNA SSBs were reported to be the source of much of the DNA damage in the brain and are associated with neurodegenerative diseases (Rass et al. 2007 ). The comet assay in the present study demonstrates that DSP4 exposure induced SSBs, rather than DSBs (Fig. 11) . Interestingly, earlier studies hypothesized that DSP4 is an alkylating compound and its neurotoxic effects might derive from uptake by NET, then alkylation of NE uptake sites by covalently binding to these sites in neurons (Ross 1976) . It was reported that the nervous system has a lower tolerance for DNA strand breaks than other tissues. For example, exposure of adult motor neurons in suspension to oxidizing agents induced SSBs followed by neuronal degeneration (Liu and Martin 2001) . Also, SSBs in neuronal DNA can physically block transcription, thereby triggering loss of cell function due to the absence of one or more essential gene products; such damage eventually leads to apoptosis. Thus, the current observations are Fig. 11 DSP4 induces single-strand DNA breaks as determined by the comet assay. SH-SY5Y cells were exposed to DSP4 in a dosedependent manner for 24 h. The cells were processed for comet assays run under neutral and alkaline conditions to identify DNA DSBs versus SSBs, respectively. N = 5 for each group consistent with the hypothesis that DSP4-induced SSBs trigger the down-regulation of noradrenergic phenotypes and lead to the neuronal degeneration.
Noradrenergic neuronal loss is an important pathogenic characteristic of neurodegenerative diseases. For example, in PD the greatest loss of neurons was found in the LC (83.2 %) rather than in the substantia nigra (77.8 %) (German et al. 1992) . In AD, LC neurons were reduced by 67.9 %, compared to 41.1 % in the nucleus basalis (Zarow et al. 2003) . Furthermore, the loss of LC neurons in PD and AD is best correlated with the duration and severity of illness (Bondareff et al. 1982; Gesi et al. 2000) . These data not only indicate that LC neuron loss is possibly due to a primary involvement of the LC itself in the early pathogenesis of PD and AD (Mann et al. 1982; Gesi et al. 2000) , but also that it might influence the onset and progression of PD and AD. Although the original hypothesis was that DSP4 affected only LC terminals (Fritschy and Grzanna 1991) , studies in recent years revealed that DSP4 also caused neuronal degeneration in the LC regions (Yu et al. 1994) . However, this action may depend on the dose and treatment period, as well as the species of animals. For example, a single dose (50 mg/kg) of DSP4 did not significantly affect neuronal number in the LC of rats (Lyons et al. 1989; Matsukawa et al. 2003; Szot et al. 2010) or rabbit (Robinson et al. 1993 ), but treatment with two or more 50 mg/kg doses resulted in LC cell loss as revealed by tyrosine hydroxylase staining in rats (Heneka et al. 2002) and mice (Heneka et al. 2006; Pugh et al. 2007; Jardanhazi-Kurutz et al. 2010; Rey et al. 2012) . It has been suggested that mice may exhibit more sensitivity to DSP4 (Fornai et al. 1996) . Accordingly, now DSP4 is used mostly in in vivo studies as a selective neurotoxin to mimic in animal models the pathology of human PD and AD in terms of degeneration of LC neurons and subsequent NEdepletion in the brain (Heneka et al. 2002; Srinivasan and Schmidt 2004) . Since little is known about how DSP4 induces neurodegeneration in vivo, it remains uncertain whether systematic administration of DSP4 would induce DNA damage in the brain similar to that observed in the present study. Nevertheless, this study provides fundamental information regarding the potential action mechanisms of DSP4 in vivo. That is, administration of DSP4 in these animal models can result in DNA SSBs which in turn activate ATM signaling pathways including formation of cH2AX and phospho-p53 ser15 , as well as other checkpoint factors and DDR processes. Therefore, therapies to minimize DNA damage may be beneficial in the future treatments of neurodegenerative diseases.
Collectively, the present studies demonstrate that DSP4 treatment significantly decreased expression of DBH/NET in a concentration-dependent manner. These alterations may be mediated through DSP4-induced SSBs, which in turn activated ATM signaling pathways to phosphorylate several DDR markers, resulting in cell cycle arrest in S-phase. These action mechanisms of DSP4 may account for its degenerative consequence after systematic administration for animal models. Further elucidation of the molecular mechanisms underlying the DSP4-induced DDR process and the genetic interactions between different DDR pathways are underway since they are of critical importance in the development of new therapeutic strategies for the treatment of many degenerative diseases.
